These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24593920)

  • 21. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Med Decis Making; 2012; 32(5):722-32. PubMed ID: 22990087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review and meta-analysis of the direct epidemiological and economic effects of seasonal influenza vaccination on healthcare workers.
    Imai C; Toizumi M; Hall L; Lambert S; Halton K; Merollini K
    PLoS One; 2018; 13(6):e0198685. PubMed ID: 29879206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives.
    Hollingsworth TD; Klinkenberg D; Heesterbeek H; Anderson RM
    PLoS Comput Biol; 2011 Feb; 7(2):e1001076. PubMed ID: 21347316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the influenza vaccination policy through mathematical modeling.
    Ho BS; Chao KM
    Int J Infect Dis; 2020 Sep; 98():71-79. PubMed ID: 32561427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.
    Jit M; Newall AT; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):834-40. PubMed ID: 23357859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A model for influenza with vaccination and antiviral treatment.
    Arino J; Brauer F; van den Driessche P; Watmough J; Wu J
    J Theor Biol; 2008 Jul; 253(1):118-30. PubMed ID: 18402981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs.
    Ibuka Y; Paltiel AD; Galvani AP
    Med Decis Making; 2012; 32(3):442-6. PubMed ID: 22472916
    [No Abstract]   [Full Text] [Related]  

  • 31. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of offering a novel remunerated community pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada.
    Pullagura GR; Waite NM; Houle SKD; Violette R; Wong WWL
    J Am Pharm Assoc (2003); 2019; 59(4):489-497.e1. PubMed ID: 30979576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Community interventions and the epidemic prevention potential.
    Halloran ME; Longini IM; Cowart DM; Nizam A
    Vaccine; 2002 Sep; 20(27-28):3254-62. PubMed ID: 12213394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Value Health; 2012; 15(6):835-42. PubMed ID: 22999133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of a Television Campaign to Promote Seasonal Influenza Vaccination Among the Elderly.
    Kim M; Yoo BK
    Value Health; 2015 Jul; 18(5):622-30. PubMed ID: 26297090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Info-gap management of public health Policy for TB with HIV-prevalence and epidemiological uncertainty.
    Ben-Haim Y; Dacso CC; Zetola NM
    BMC Public Health; 2012 Dec; 12():1091. PubMed ID: 23249291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
    Thommes EW; Kruse M; Kohli M; Sharma R; Noorduyn SG
    Hum Vaccin Immunother; 2017 Apr; 13(4):867-876. PubMed ID: 27858509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A; Roiz J; Aballea S
    PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.